Feed

Stereotactic body radiation therapy (SBRT)/stereotactic ablative radiation therapy (SABR), leveraging its precision and high efficiency, has become an important radical treatment modality for early-stage non-small cell lung cancer, particularly suitable for patients who are inoperable or refuse surgery. With advances in radiotherapy technology and in-depth clinical research, its clinical applications have been continuously expanding. To standardize clinical practice, improve treatment homogenization, and facilitate collaborative research, the expert panel developed this consensus based on domestic and international evidence and practical experience. This consensus covers five core components: (1) reviewing the developmental history and key research outcomes of SBRT/SABR; (2) defining standards for equipment configuration, treatment planning, and quality assurance; (3) refining patient selection, treatment workflow, and efficacy evaluation; (4) discussing strategies and safety management of SBRT/SABR combined with immunotherapy/targeted therapy; (5) providing recommendations for managing complex scenarios such as central lung cancer. This consensus aims to provide clinicians with standardized guidance, optimize treatment decisions, enhance patient benefits, and promote the high-quality development of SBRT/SABR in China, ultimately benefiting a broader population of patients with lung cancer.